Ball S G, Sokolov J, Chin W W
Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.
J Mol Endocrinol. 1997 Oct;19(2):137-47. doi: 10.1677/jme.0.0190137.
Recent data have suggested that the iodothyronine, 3,5-diiodo-l-thyronine (T2), has selective thyromimetic activity. In vivo, T2 has been shown to suppress TSH levels at doses that do not produce significant peripheral manifestations of thyroid hormone activity. Furthermore, T2 has been shown to produce smaller increments in peripheral indices of thyroid status than does T3, when doses resulting in equivalent suppression of circulating TSH are compared. We have assessed the selective thyromimetic activity of T2 in vivo and in vitro, and performed in vitro studies to assess the potential molecular basis for these selective properties. T2 was 100-fold less potent than T3 in stimulating GH mRNA levels in GH3 cells. In contrast, the iodothyronines were almost equivalent in their ability to downregulate TRbeta2 mRNA levels in this cell line. Both 3,3'-diiodo-L-thyronine and thyronine exhibited no significant thyromimetic effects on either process. In vivo, doses of T2 and T3 that were equivalent in their induction of hepatic malic enzyme (ME) mRNA did not produce equivalent suppression of circulating TSH, with T2 being only 27% as effective as T3. T2 was up to 500-fold less potent than T3 in displacing [125I]-T3 from in vitro translated specific nuclear receptors (TRs) and GH3 cell nuclear extracts. Electrophoretic mobility shift assays, assessing the ability of T2 to produce dissociation of TRbeta1 homodimers from inverted palindrome T3 response elements, indicated that T2 was also 1000-fold less potent than T3 in this respect. These data confirm that T2 has significant thyromimetic activity, and that this activity is selective both in vivo and in vitro. However, there are no data to support a selective central effect, T2 being relatively more potent in stimulating hepatic ME mRNA than in suppression of TSH in vivo. The basis for this differential thyromimetic activity is not selective affinity of the different TR isoforms for T2, or divergent properties of T2 in competitive binding and functional assays in vitro.
近期数据表明,碘甲腺原氨酸3,5-二碘-L-甲状腺原氨酸(T2)具有选择性拟甲状腺活性。在体内,已证明T2在不产生甲状腺激素活性明显外周表现的剂量下可抑制促甲状腺激素(TSH)水平。此外,当比较导致循环TSH等效抑制的剂量时,已证明T2在外周甲状腺状态指标上产生的增量比T3小。我们评估了T2在体内和体外的选择性拟甲状腺活性,并进行了体外研究以评估这些选择性特性的潜在分子基础。在GH3细胞中,T2刺激生长激素(GH)mRNA水平的效力比T3低100倍。相比之下,碘甲腺原氨酸在下调该细胞系中TRβ2 mRNA水平的能力上几乎相当。3,3'-二碘-L-甲状腺原氨酸和甲状腺原氨酸对这两个过程均未表现出明显的拟甲状腺作用。在体内,诱导肝苹果酸酶(ME)mRNA等效的T2和T3剂量并未产生等效的循环TSH抑制,T2的效力仅为T3的27%。在从体外翻译的特异性核受体(TRs)和GH3细胞核提取物中置换[125I]-T3方面,T2的效力比T3低多达500倍。电泳迁移率变动分析评估了T2使TRβ1同二聚体从反向回文T3反应元件解离的能力,结果表明在这方面T2的效力也比T3低1000倍。这些数据证实T2具有显著的拟甲状腺活性,且该活性在体内和体外均具有选择性。然而,没有数据支持其具有选择性中枢效应,在体内T2刺激肝ME mRNA相对比抑制TSH更有效。这种差异拟甲状腺活性的基础并非不同TR异构体对T2的选择性亲和力,也不是T2在体外竞争结合和功能测定中的不同特性。